Month: April 2023

ContraFect Announces First Patient Dosed in the Phase 1b/2 Study of Exebacase in Patients with Chronic Prosthetic Joint Infections of the Knee

YONKERS, N.Y., April 26, 2023 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery...

Allied Corp Signs Joint Venture With Blueberries Medical Corp. to Expand Product Offering and Bring Derivative Products to Global Markets

KELOWNA, British Columbia, April 26, 2023 (GLOBE NEWSWIRE) -- Allied Corp. ("Allied" or the “Company”) (OTCQB: ALID), a leading cannabis...

SAB Biotherapeutics Announces Positive Results from Phase 3 Trial of SAB-185 in Patients with COVID-19 at High-Risk for Severe Complications

SAB-185, a human IgG1 (polyclonal) antibody therapeutic candidate, demonstrated benefit in sustained symptom resolution in patients with Omicron variants of...

error: Content is protected !!